HIV prevention, vaccine research progressing

In a guest post on the Center for Global Health Policy's "Science Speaks" blog, Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative (IAVI), and William Snow, director of the Global HIV Vaccine Enterprise, discuss the recent AIDS Vaccine 2012 Conference that was held in Boston. "There has been so much progress in every aspect of HIV prevention research over the last three years that [researchers] had plenty to report," they write, adding, "[I]t is increasingly clear that defeating HIV will require the combined application of a number of interventions." They review the results of several studies and comments from several speakers and conclude, "[S]cientific partnership across borders and oceans has long been a hallmark of HIV vaccine development. That, after all, is what brought the field to where it is now: on the verge of a transformation" (Barton, 10/1).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17